Secukinumab approved by NICE for severe psoriasis

The monoclonal antibody secukinumab (Cosentyx) has been endorsed by NICE for use in patients with severe plaque psoriasis who have not responded to, or have an intolerance or contraindication to, standard systemic therapies

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content. View our subscription and registration options.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us



  • Limited free articles a month 
  • Free email bulletins

Register Now

Take a 30-day trial

  • Join MIMS now and pay nothing for the first 30 days

Sign Up